Abstract
The presence of autoantibodies in apparently healthy individuals has been increasingly recognized. Although some of these individuals are in preclinical stages of a disease such as systemic lupus erythematosus (SLE), many will not develop SLE or any other autoimmune disorder. The high prevalence of autoreactivity in the population in fact suggests that autoantibodies are expressed as part of a healthy immune response, and other data have clearly shown that some autoantibodies have important immune regulatory functions. These observations leave open questions regarding when and how benign autoimmunity develops into disease. If the transition from preclinical autoimmunity to a clinical disorder such as SLE could be predicted, early and thus potentially more effective intervention might be possible and cures might even become a reality. Furthermore, increased understanding of mechanisms by which autoantibodies are kept in check can identify new approaches to aborting or preventing disease transformations. In this article, we summarize the current findings regarding the presence of SLE-associated antibodies in apparently healthy individuals, and provide our opinions on what such discoveries might tell us about the roles of autoantibodies in the development of disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Lateef, A. & Petri, M. Unmet medical needs in systemic lupus erythematosus. Arthritis Res. Ther. 14 (Suppl. 4), S4 (2012).
Rahman, A. & Isenberg, D. A. Systemic lupus erythematosus. N. Engl. J. Med. 358, 929–939 (2008).
Nossent, J. et al. Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus 19, 949–956 (2010).
Friou, G. J., Finch, S. C. & Detre, K. D. Interaction of nuclei and globulin from lupus erythematosis serum demonstrated with fluorescent antibody. J. Immunol. 80, 324–329 (1958).
Meroni, P. & Schur, P. ANA screening: an old test with new recommendations. Ann. Rheum. Dis. 69, 1420–1422 (2010).
Arbuckle, M. et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 349, 1526–1533 (2003).
Sokolove, J. et al. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS ONE 7, e35296 (2012).
Arend, W. P. & Firestein, G. S. Pre-rheumatoid arthritis: predisposition and transition to clinical synovitis. Nat. Rev. Rheumatol. 8, 573–586 (2012).
Bluestone, J. A., Herold, K. & Eisenbarth, G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 464, 1293–1300 (2010).
Wandstrat, A. et al. Autoantibody profiling to identify individuals at risk for systemic lupus erythematosus. J. Autoimmun. 27, 153–160 (2006).
Feldman, C. H. et al. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000–2004. Arthritis Rheum. 65, 753–763 (2013).
Li, Q. Z. et al. Risk factors for ANA positivity in healthy persons. Arthritis Res. Ther. 13, R38 (2011).
Fritzler, M. J. Toward a new autoantibody diagnostic orthodoxy: understanding the bad, good and indifferent. Autoimmun. Highlights 3, 51–58 (2012).
Fernandez, S. et al. Prevalence of antinuclear autoantibodies in the serum of normal blood dornors. Rev. Hosp. Clin. Fac. Med. Sao Paulo 58, 315–319 (2003).
Tan, E. M. et al. Range of antinuclear antibodies in “healthy” individuals. Arthritis Rheum. 40, 1601–1611 (1997).
Greer, J. M. & Panush, R. S. Incomplete lupus erythematosus. Arch. Intern. Med. 149, 2473–2476 (1989).
Marin, G. G., Cardiel, M. H., Cornejo, H. & Viveros, M. E. Prevalence of antinuclear antibodies in 3 groups of healthy individuals: blood donors, hospital personnel, and relatives of patients with autoimmune diseases. J. Clin. Rheumatol. 15, 325–329 (2009).
Eriksson, C. et al. Autoantibodies predate the onset of systemic lupus erythematosus in northern Sweden. Arthritis Res. Ther. 13, R30 (2011).
Mahler, M. et al. Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases. J. Rheumatol. 39, 2104–2110 (2012).
Satoh, M. et al. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum. 64, 2319–2327 (2012).
Sherer, Y., Gorstein, A., Fritzler, M. J. & Shoenfeld, Y. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin. Arthritis Rheum. 34, 501–537 (2004).
Kumar, S. et al. Lupus autoantibodies to native DNA preferentially bind DNA presented on PolIV. Immunology 114, 418–427 (2005).
Xia, Y. et al. The constant region contributes to the antigenic specificity and renal pathogenicity of murine anti-DNA antibodies. J. Autoimmun. 39, 398–411 (2012).
Popovic, K., Brauner, S., Ek, M., Wahren-Herlenius, M. & Nyberg, F. Fine specificity of the Ro/SSA autoantibody response in relation to serological and clinical findings in 96 patients with self-reported cutaneous symptoms induced by the sun. Lupus 16, 10–17 (2007).
Tzaneva, S., Volc-Platzer, B., Kittler, H., Hönigsmann, H. & Tanew, A. Antinuclear antibodies in patients with polymorphic light eruption: a long-term follow-up study. Br. J. Dermatol. 158, 1050–1054 (2008).
Tan, E. et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 25, 1271–1277 (1982).
Hochberg, M. C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 40, 1725 (1997).
Petri, M. et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 64, 2677–2686 (2012).
Vilá, L. M., Mayor, A. M., Valentín, A. H., García-Soberal, M. & Vilá, S. Clinical outcome and predictors of disease evolution in patients with incomplete lupus erythematosus. Lupus 9, 110–115 (2000).
Li, Q. et al. Protein array autoantibody profiles for insights into systemic lupus erythematosus and incomplete lupus syndromes. Clin. Exp. Immunol. 147, 60–70 (2007).
Olsen, N. J. et al. Autoantibody profiling to follow evolution of lupus syndromes. Arthritis Res. Ther. 14, R174 (2012).
Werwitzke, S. et al. Inhibition of lupus disease by anti-double-stranded DNA antibodies of the IgM isotype in the (NZB x NZW)F1 mouse. Arthritis Rheum. 52, 3629–3638 (2005).
Grönwall, C. et al. IgM autoantibodies to distinct apoptosis-associated antigens correlate with protection from cardiovascular events and renal disease in patients with SLE. Clin. Immunol. 142, 390–398 (2012).
Pauklin, S., Sernández, I. V., Bachmann, G., Ramiro, A. R. & Petersen-Mahrt, S. K. Estrogen directly activates AID transcription and function. J. Exp. Med. 206, 99–111 (2009).
Tessnow, A. H., Olsen, N. J. & Kovacs, W. J. Expression of humoral autoimmunity is related to androgen receptor CAG repeat length in men with systemic lupus erythematosus. J. Clin. Immunol. 31, 567–573 (2011).
Sakiani, S., Olsen, N. J. & Kovacs, W. J. Gonadal steroids and humoral immunity. Nat. Rev. Endocrinol. 9, 56–62 (2013).
Villalta, D. et al. Anti-dsDNA antibody isotypes in systemic lupus erythematosus: IgA in addition to IgG anti-dsDNA help to identify glomerulonephritis and active disease. PLoS ONE 8, e71458 (2013).
Charles, N. & Rivera, J. Basophils and autoreactive IgE in the pathogenesis of systemic lupus erythematosus. Curr. Allergy Asthma Rep. 11, 378–387 (2011).
Hoch, S., Schur, P. H. & Schwaber, J. Frequency of anti-DNA antibody producing cells from normals and patients with systemic lupus erythematosus. Clin. Immunol. Immunopathol. 27, 28–37 (1983).
Aringer, M. & Vital, E. Lots of autoantibodies equal lupus? Arthritis Res. Ther. 15, 102 (2013).
Zandman-Goddard, G., Solomon, M., Rosman, Z., Peeva, E. & Shoenfeld, Y. Environment and lupus-related diseases. Lupus 21, 241–250 (2012).
Wahren-Herlenius, M. & Dörner, T. Immunopathogenic mechanisms of systemic autoimmune disease. Lancet 382, 819–831 (2013).
Costenbader, K. H., Feskanich, D., Stampfer, M. J. & Karlson, E. W. Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. Arthritis Rheum. 56, 1251–1262 (2007).
Costenbader, K. H. & Karlson, E. W. Cigarette smoking and autoimmune disease: what can we learn from epidemiology? Lupus 15, 737–745 (2006).
Cooper, G. S. et al. Occupational and environmental exposures and risk of systemic lupus erythematosus: silica, sunlight, solvents. Rheumatology (Oxford) 49, 2172–2180 (2010).
Schmidt, E., Tony, H., Bröcker, E. & Kneitz, C. Sun-induced life-threatening lupus nephritis. Ann. NY Acad. Sci. 1108, 35–40 (2007).
Harley, J. B. & James, J. A. Epstein-Barr virus infection induces lupus autoimmunity. Bull. NYU Hosp. Jt Dis. 64, 45–50 (2006).
Ritterhouse, L. L. et al. Vitamin D deficiency is associated with an increased autoimmune response in healthy individuals and in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 70, 1569–1574 (2011).
Agmon-Levin, N., Hughes, G. R. & Shoenfeld, Y. The spectrum of ASIA: 'Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants'. Lupus 21, 118–120 (2012).
Azizah, M. R., Azila, M. N., Zulkifli, M. N. & Norita, T. Y. The prevalence of antinuclear, anti-dsDNA, anti-Sm and anti-RNP antibodies in a group of healthy blood donors. Asian Pac. J. Allergy Immunol. 14, 125–128 (1996).
von Mühlen, C. A. & Tan, E. M. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin. Arthritis Rheum. 24, 323–358 (1995).
Acknowledgements
The authors gratefully acknowledge Catherine Abendroth, Penn State Milton S. Hershey Medical Center, PA, USA, and Kari Connolly, University of California San Francisco Medical Center, CA, USA, for providing photomicrographs used in Figure 2.
Author information
Authors and Affiliations
Contributions
Both authors made substantial contributions to all stages of the preparation of this manuscript for submission.
Corresponding author
Ethics declarations
Competing interests
N. J. Olsen has received research funding from NovoNordisk, Questcor, Roche/Genentech and Savient, and has an equity interest in ArthroChip. D. R. Karp has received research funding from BMS, Human Genome Sciences/GSK, Janssen and Sanofi.
Rights and permissions
About this article
Cite this article
Olsen, N., Karp, D. Autoantibodies and SLE—the threshold for disease. Nat Rev Rheumatol 10, 181–186 (2014). https://doi.org/10.1038/nrrheum.2013.184
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2013.184
This article is cited by
-
Serological and clinical associations of autoantibodies in Chinese patients with new-onset systemic lupus erythematosus
Scientific Reports (2023)
-
High throughput sequencing revealed enhanced cell cycle signaling in SLE patients
Scientific Reports (2023)
-
Endocapillary hypercellularity levels are associated with early complete remission in children with class IV lupus nephritis as the initial presentation of SLE
BMC Nephrology (2022)
-
T Cell Abnormalities in the Pathogenesis of Systemic Lupus Erythematosus: an Update
Current Rheumatology Reports (2021)
-
Increased MLKL mRNA level in the PBMCs is correlated with autoantibody production, renal involvement, and SLE disease activity
Arthritis Research & Therapy (2020)